U.S. Markets open in 4 hrs 47 mins
  • S&P Futures

    4,381.50
    -93.25 (-2.08%)
     
  • Dow Futures

    33,992.00
    -261.00 (-0.76%)
     
  • Nasdaq Futures

    14,308.00
    -193.00 (-1.33%)
     
  • Russell 2000 Futures

    2,008.40
    -23.30 (-1.15%)
     
  • Crude Oil

    0 (0)
     
  • Gold

    1,841.10
    -0.60 (-0.03%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     
  • BTC-USD

    36,381.69
    +1,712.44 (+4.94%)
     
  • CMC Crypto 200

    823.79
    +13.18 (+1.63%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • QGEN
  • BRBR
  • NVST
  • BAX

QIAGEN N.V.’s QGEN overdependence on relationships with collaborative partners and foreign exchange headwinds are major downsides. The stock currently has a Zacks Rank #5 (Strong Sell).

Over the past six months, QIAGEN has underperformed the industry it belongs to. The stock has declined 6.1% compared with the industry’s 3.1% fall.

With gradually falling COVID-19 cases, since the beginning of 2021, the company’s COVID-19 testing related product lines are seeing significant decline in sales. This trend should continue through the rest of the year. Added to this, we are worried about the huge debt on its balance sheet. As per the last report, the company’s debt in the first quarter of 2021 was much higher than the quarter-end cash and cash equivalent, and short-term investments level. The quarter’s total debt-to-capital of 40.4% indicates a leveraged balance sheet.

QIAGEN N.V. Price

QIAGEN N.V. Price
QIAGEN N.V. Price

QIAGEN N.V. price | QIAGEN N.V. Quote

Stiff competition from firms providing competitive pre-analytical solutions and other products used by QIAGEN’s customers persist. Contraction of gross margin in the reported quarter is worrying too. High exposure to risks of foreign currency movement is observed.

On a positive note, QIAGEN exited the first quarter of 2021 with better-than-expected revenues and earnings. It registered revenue growth across all geographies and both its operating segments in the first quarter. The company’s high level of sales for product groups used in the COVID-19 pandemic response drove the top line. Sample technologies products witnessed strong year-over-year growth driven by double-digit constant exchange rate or CER growth for non-COVID products, particularly consumables kits for DNA extraction. Also, product groups used in COVID-19 testing, particularly automated RNA solutions, saw solid demand during the reported quarter.

During the first quarter, QIAGEN’s QuantiFERON-TB sales improved 22% led by strong demand in the United States. Sales of QIAstat-Dx and NeuMoDx solutions remained at a high level as well. The company also registered high level of COVID-19 testing products sales during the reported quarter. QIAGEN’s QuantiFERON-TB Access sales registered double-digit growth during the first quarter of 2021. The company, on the first-quarter earnings call, confirmed the launch of QIAreach-TB in 2021, which is a new version of QuantiFERON-TB test. The company also noted that it is on track to achieve 2021 sales goal of more than $230 million for the QuantiFERON franchise.

Key Picks

A few better-ranked stocks from the broader medical space are Envista Holdings Corporation NVST, BellRing Brands, Inc. BRBR and Baxter International Inc. BAX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 26%.

BellRing Brands has an estimated long-term earnings growth rate of 22%.

Baxter International has a projected long-term earnings growth rate of 9%.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Baxter International Inc. (BAX) : Free Stock Analysis Report

QIAGEN N.V. (QGEN) : Free Stock Analysis Report

Envista Holdings Corporation (NVST) : Free Stock Analysis Report

BellRing Brands, Inc. (BRBR) : Free Stock Analysis Report

To read this article on Zacks.com click here.